ID

31777

Descripción

CLARITY Extension Study; ODM derived from: https://clinicaltrials.gov/show/NCT00641537

Link

https://clinicaltrials.gov/show/NCT00641537

Palabras clave

Versiones (1)
  1. 27/9/18 27/9/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

27 de septiembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00641537

Inglés

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00641537

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
randomized in trial 25643 and satisfied one of the following:
Descripción

Randomization Clinical Trial Specified

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0034656
UMLS CUI [1,2]
C0008976
UMLS CUI [1,3]
C0205369
completed randomized treatment course and scheduled visits for the full 96 weeks; or
Descripción

Therapeutic procedure Completed | Visits Scheduled Completed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205197
UMLS CUI [2,1]
C0008952
UMLS CUI [2,2]
C0205539
UMLS CUI [2,3]
C0205197
did not complete the randomized treatment course in trial 25643 but elected to receive rescue treatment with rebif®, another beta-interferon, or glatiramer acetate and completed scheduled clinic visits for the full 96 weeks; or
Descripción

Therapeutic procedure Incomplete | Rebif | Interferon-beta | glatiramer acetate | Clinic Visits Scheduled Completed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205257
UMLS CUI [2]
C0752980
UMLS CUI [3]
C0015980
UMLS CUI [4]
C0289884
UMLS CUI [5,1]
C0008952
UMLS CUI [5,2]
C0205539
UMLS CUI [5,3]
C0205197
did not complete the randomized treatment course in trial 25643, declined rescue with rebif®, another beta-interferon, or glatiramer acetate and still completed scheduled clinic visits for the full 96 weeks; or
Descripción

Therapeutic procedure Incomplete | Rebif Rejected | Interferon-beta Rejected | Glatiramer acetate Rejected | Clinic Visits Scheduled Completed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205257
UMLS CUI [2,1]
C0752980
UMLS CUI [2,2]
C1548437
UMLS CUI [3,1]
C0015980
UMLS CUI [3,2]
C1548437
UMLS CUI [4,1]
C0289884
UMLS CUI [4,2]
C1548437
UMLS CUI [5,1]
C0008952
UMLS CUI [5,2]
C0205539
UMLS CUI [5,3]
C0205197
did not complete the randomized treatment course in trial 25643, were not eligible for rescue option with rebif®, and still completed scheduled clinic visits for the full 96 weeks
Descripción

Therapeutic procedure Incomplete | Ineligibility Rebif | Clinic Visits Scheduled Completed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205257
UMLS CUI [2,1]
C1512714
UMLS CUI [2,2]
C0752980
UMLS CUI [3,1]
C0008952
UMLS CUI [3,2]
C0205539
UMLS CUI [3,3]
C0205197
male or female, between 18 and 65 years of age (inclusive, at time of informed consent for trial 25643)
Descripción

Age | Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0021430
no medical history or evidence of latent tuberculosis infection (ltbi) or tuberculosis (tb), as evidenced by tb skin test or chest x-ray
Descripción

Latent Tuberculosis Absent TB Skin Test | Tuberculosis Absent TB Skin Test | Latent Tuberculosis Absent Chest X-ray | Tuberculosis Absent Chest X-ray

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1609538
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C3282342
UMLS CUI [2,1]
C0041296
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C3282342
UMLS CUI [3,1]
C1609538
UMLS CUI [3,2]
C0332197
UMLS CUI [3,3]
C0039985
UMLS CUI [4,1]
C0041296
UMLS CUI [4,2]
C0332197
UMLS CUI [4,3]
C0039985
all of the following laboratory hematologic parameters evaluated as normal (as define below, inclusively) within 28 days of first dosing of blinded study medication at study day 1:
Descripción

Parameters Hematologic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0449381
UMLS CUI [1,2]
C0205488
hemoglobin = 11.6 to 16.2 gram per deciliter (g/dl)
Descripción

Hemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0518015
leukocytes (total white blood cell) = 4.1 to 12.3*10^3 per microliter
Descripción

White Blood Cell Count procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023508
absolute lymphocyte count (alc) = 1.02 to 3.36*10^3 per microliter
Descripción

Absolute lymphocyte count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3544087
absolute neutrophil count (anc) = 2.03 to 8.36*10^3 per microliter
Descripción

Absolute neutrophil count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0948762
platelet count = 140 to 450*10^3 per microliter
Descripción

Platelet Count measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032181
other protocol-defined inclusion/exclusion criteria may apply
Descripción

Eligibility Criteria Study Protocol

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who were not enrolled in trial 25643
Descripción

Enrollment Absent | Clinical Trial Specified

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1516879
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0008976
UMLS CUI [2,2]
C0205369
subject has moderate to severe renal impairment
Descripción

Renal Insufficiency Moderate | Renal Insufficiency Severe

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1565489
UMLS CUI [1,2]
C0205081
UMLS CUI [2,1]
C1565489
UMLS CUI [2,2]
C0205082
use of mitoxantrone, total lymphoid irradiation, myelosuppressive therapy, campath-1h, cyclophosphamide, azathioprine, methotrexate or natalizumab at any time during and since trial 25643
Descripción

Mitoxantrone | Lymphatic Irradiation Total | Myelosuppressive Therapy | Campath 1H | Cyclophosphamide | Azathioprine | Methotrexate | natalizumab

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0026259
UMLS CUI [2,1]
C0024230
UMLS CUI [2,2]
C0439810
UMLS CUI [3]
C1513793
UMLS CUI [4]
C1178562
UMLS CUI [5]
C0010583
UMLS CUI [6]
C0004482
UMLS CUI [7]
C0025677
UMLS CUI [8]
C1172734
use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (ivig) or plasmapheresis at any time during and since trial 25643
Descripción

Cytokine | Anti-cytokine therapy | Immunoglobulins, Intravenous | Plasmapheresis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079189
UMLS CUI [2]
C0281178
UMLS CUI [3]
C0085297
UMLS CUI [4]
C0032134
treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within 28 days before study day 1
Descripción

Adrenal Cortex Hormones Oral | CORTICOSTEROIDS FOR SYSTEMIC USE | Adrenocorticotropic hormone

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C1527415
UMLS CUI [2]
C3653708
UMLS CUI [3]
C0001655
Volver a la parte superior de la página

Similar models

Eligibility Relapsing-Remitting Multiple Sclerosis NCT00641537

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Randomization Clinical Trial Specified
Item
randomized in trial 25643 and satisfied one of the following:
boolean
C0034656 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0205369 (UMLS CUI [1,3])
Therapeutic procedure Completed | Visits Scheduled Completed
Item
completed randomized treatment course and scheduled visits for the full 96 weeks; or
boolean
C0087111 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0008952 (UMLS CUI [2,1])
C0205539 (UMLS CUI [2,2])
C0205197 (UMLS CUI [2,3])
Therapeutic procedure Incomplete | Rebif | Interferon-beta | glatiramer acetate | Clinic Visits Scheduled Completed
Item
did not complete the randomized treatment course in trial 25643 but elected to receive rescue treatment with rebif®, another beta-interferon, or glatiramer acetate and completed scheduled clinic visits for the full 96 weeks; or
boolean
C0087111 (UMLS CUI [1,1])
C0205257 (UMLS CUI [1,2])
C0752980 (UMLS CUI [2])
C0015980 (UMLS CUI [3])
C0289884 (UMLS CUI [4])
C0008952 (UMLS CUI [5,1])
C0205539 (UMLS CUI [5,2])
C0205197 (UMLS CUI [5,3])
Therapeutic procedure Incomplete | Rebif Rejected | Interferon-beta Rejected | Glatiramer acetate Rejected | Clinic Visits Scheduled Completed
Item
did not complete the randomized treatment course in trial 25643, declined rescue with rebif®, another beta-interferon, or glatiramer acetate and still completed scheduled clinic visits for the full 96 weeks; or
boolean
C0087111 (UMLS CUI [1,1])
C0205257 (UMLS CUI [1,2])
C0752980 (UMLS CUI [2,1])
C1548437 (UMLS CUI [2,2])
C0015980 (UMLS CUI [3,1])
C1548437 (UMLS CUI [3,2])
C0289884 (UMLS CUI [4,1])
C1548437 (UMLS CUI [4,2])
C0008952 (UMLS CUI [5,1])
C0205539 (UMLS CUI [5,2])
C0205197 (UMLS CUI [5,3])
Therapeutic procedure Incomplete | Ineligibility Rebif | Clinic Visits Scheduled Completed
Item
did not complete the randomized treatment course in trial 25643, were not eligible for rescue option with rebif®, and still completed scheduled clinic visits for the full 96 weeks
boolean
C0087111 (UMLS CUI [1,1])
C0205257 (UMLS CUI [1,2])
C1512714 (UMLS CUI [2,1])
C0752980 (UMLS CUI [2,2])
C0008952 (UMLS CUI [3,1])
C0205539 (UMLS CUI [3,2])
C0205197 (UMLS CUI [3,3])
Age | Informed Consent
Item
male or female, between 18 and 65 years of age (inclusive, at time of informed consent for trial 25643)
boolean
C0001779 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Latent Tuberculosis Absent TB Skin Test | Tuberculosis Absent TB Skin Test | Latent Tuberculosis Absent Chest X-ray | Tuberculosis Absent Chest X-ray
Item
no medical history or evidence of latent tuberculosis infection (ltbi) or tuberculosis (tb), as evidenced by tb skin test or chest x-ray
boolean
C1609538 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C3282342 (UMLS CUI [1,3])
C0041296 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C3282342 (UMLS CUI [2,3])
C1609538 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0039985 (UMLS CUI [3,3])
C0041296 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0039985 (UMLS CUI [4,3])
Parameters Hematologic
Item
all of the following laboratory hematologic parameters evaluated as normal (as define below, inclusively) within 28 days of first dosing of blinded study medication at study day 1:
boolean
C0449381 (UMLS CUI [1,1])
C0205488 (UMLS CUI [1,2])
Hemoglobin measurement
Item
hemoglobin = 11.6 to 16.2 gram per deciliter (g/dl)
boolean
C0518015 (UMLS CUI [1])
White Blood Cell Count procedure
Item
leukocytes (total white blood cell) = 4.1 to 12.3*10^3 per microliter
boolean
C0023508 (UMLS CUI [1])
Absolute lymphocyte count
Item
absolute lymphocyte count (alc) = 1.02 to 3.36*10^3 per microliter
boolean
C3544087 (UMLS CUI [1])
Absolute neutrophil count
Item
absolute neutrophil count (anc) = 2.03 to 8.36*10^3 per microliter
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count = 140 to 450*10^3 per microliter
boolean
C0032181 (UMLS CUI [1])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Enrollment Absent | Clinical Trial Specified
Item
subjects who were not enrolled in trial 25643
boolean
C1516879 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0008976 (UMLS CUI [2,1])
C0205369 (UMLS CUI [2,2])
Renal Insufficiency Moderate | Renal Insufficiency Severe
Item
subject has moderate to severe renal impairment
boolean
C1565489 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C1565489 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
Mitoxantrone | Lymphatic Irradiation Total | Myelosuppressive Therapy | Campath 1H | Cyclophosphamide | Azathioprine | Methotrexate | natalizumab
Item
use of mitoxantrone, total lymphoid irradiation, myelosuppressive therapy, campath-1h, cyclophosphamide, azathioprine, methotrexate or natalizumab at any time during and since trial 25643
boolean
C0026259 (UMLS CUI [1])
C0024230 (UMLS CUI [2,1])
C0439810 (UMLS CUI [2,2])
C1513793 (UMLS CUI [3])
C1178562 (UMLS CUI [4])
C0010583 (UMLS CUI [5])
C0004482 (UMLS CUI [6])
C0025677 (UMLS CUI [7])
C1172734 (UMLS CUI [8])
Cytokine | Anti-cytokine therapy | Immunoglobulins, Intravenous | Plasmapheresis
Item
use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (ivig) or plasmapheresis at any time during and since trial 25643
boolean
C0079189 (UMLS CUI [1])
C0281178 (UMLS CUI [2])
C0085297 (UMLS CUI [3])
C0032134 (UMLS CUI [4])
Adrenal Cortex Hormones Oral | CORTICOSTEROIDS FOR SYSTEMIC USE | Adrenocorticotropic hormone
Item
treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within 28 days before study day 1
boolean
C0001617 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C3653708 (UMLS CUI [2])
C0001655 (UMLS CUI [3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial